Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease.
Horvath
J
J
Department of Neurology, Geneva University Hospitals and Medical School, Geneva, Switzerland.
Coeytaux
A
A
Jallon
P
P
Landis
T
T
Temperli
P
P
Burkhard
P R
PR
D000368:Aged; D000588:Amines / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects; D001284:Atrophy / Q000473:pathology; D001479:Basal Ganglia / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D001921:Brain / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D001925:Brain Damage, Chronic / Q000139:chemically induced* / Q000175:diagnosis* / Q000503:physiopathology; D002220:Carbamazepine / Q000009:adverse effects*; D003072:Cognition Disorders / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D007562:Creutzfeldt-Jakob Syndrome / Q000175:diagnosis* / Q000503:physiopathology; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D003704:Dementia / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D003937:Diagnosis, Differential; D003951:Diagnostic Errors / Q000517:prevention & control*; D018450:Disease Progression; D004409:Dyskinesia, Drug-Induced / Q000473:pathology / Q000503:physiopathology; D004569:Electroencephalography; D000077206:Gabapentin; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D020127:Recovery of Function / Q000502:physiology; D014277:Trigeminal Neuralgia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D018712:Analgesics, Non-Narcotic; D003509:Cyclohexanecarboxylic Acids; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin